Therapy For Severe Psoriasis

A brand-new title in the field of dermatology, Therapy for Severe Psoriasis provides the ultimate coverage of the treatment options available for today's most serious cases, including biologics and oral therapies. It features discussions of the newest drug therapies, recent FDA-approved biosimilars, and combination approaches to care, while an overview chapter was designed to aid those new to the field in understanding the nuances of difficult-to-treat subtypes of psoriasis. Comprehensive and focused, Therapy for Severe Psoriasis will be a welcome addition to the library of any dermatologist seeking in-depth information on the challenges of this condition. Each of the 16 chapters includes either an in-depth focus on a single therapy or an overview of a unique aspect of psoriasis, including: UVB therapy, methotrexate, acitretin, cyclosporine, apremilast, etanercept, infliximab, adalimumab, ustekinumab, secukinumab, and ixekizumab. Takes an evidence-based approach to hard-to-treat severe psoriasis. Discusses the newest drug therapies (such as ixekizumab), plus recent FDA-approved biosimilars, a topic unique to this particular psoriasis text. Presents combination approaches for instances when standard treatments are not successful. Includes an overview chapter to help beginners understand the nuances of the disorder.

Written by experts in the dermatology field, this new fourth edition of Moderate-to-Severe Psoriasis discusses the current use of biologics and other pharmacologic and phototherapy treatments for moderate-to-severe psoriasis. Illustrated with high quality color figures, this standalone text emphasizes safe and effective treatments for the psoriasis patient that are perfect for the dermatologist in daily practice. New to this edition are chapters on day treatment programs, new agents, erythrodermic and pustular psoriasis, special populations, and pharmacogenetics.

A brand-new title in the field of dermatology, Therapy for Severe Psoriasis provides the ultimate coverage of the treatment options available for today's most serious cases, including biologics and oral therapies. It features discussions of the newest drug therapies, recent FDA-approved biosimilars, and combination approaches to care, while an overview chapter was designed to aid those new to the field in understanding the nuances of difficult-to-treat subtypes of psoriasis. Comprehensive and focused, Therapy for Severe Psoriasis will be a welcome addition to the library of any dermatologist seeking in-depth information on the challenges of this condition. Each of the 16 chapters includes either an in-depth focus on a single therapy or an overview of a unique aspect of psoriasis, including: UVB therapy, methotrexate, acitretin, cyclosporine, apremilast, etanercept, infliximab, adalimumab, ustekinumab, secukinumab, and ixekizumab. Takes an evidence-based approach to hard-to-treat severe psoriasis. Discusses the newest drug therapies (such as ixekizumab), plus recent FDA-approved biosimilars, a topic unique to this particular psoriasis text. Presents combination approaches for instances when standard treatments are not successful. Includes an overview chapter to help beginners understand the nuances of the disorder. Expert Consult eBook version included with purchase. This enhanced eBook experience allows you to search all of the text, figures, images, and references from the book on a variety of devices.

This handbook features updated chapters discussing the latest and most commonly prescribed therapies for patients with moderate-to-severe psoriasis. Topics include the management of paediatric patients and patients with psoriatic arthritis.

Biologic therapy is a treatment that strives to modulate a patient's immune system to fight a given disease. In psoriasis, a skin disorder that is partly caused by a dysregulated immune system resulting in well-demarcated red areas of the skin with white scales, biologic therapy has the potential to vastly improve upon patient outcomes by minimizing the symptoms of this disease while maximizing the safety profile of the therapy. This book offers an up-to-date and comprehensive review on biologic therapy for the treatment of psoriasis. With over 10 FDA approved biologic agents for psoriasis (with more in the pipeline), confusion exists among providers regarding which agent is best for a particular patient. Chapters cover all FDA approved psoriasis biologic agents (including pipeline agents) for use in pediatric, adult, and geriatric patients. This book is unique in that it will not only cover cutting edge treatment principles based on the latest research, it will also be one of the most comprehensive reviews of psoriasis biologics in the COVID-19 era. Biologic Therapy for Psoriasis is a must-have resource for board certified dermatologists and rheumatologists, dermatology and rheumatology residents and fellows, dermatology physician assistants, nurse practitioners and medical students. The ultimate goal of this book is to improve patient care by making the busy practicing dermatology provider more adept with these particular therapies.

Treatments for psoriasis, besides affecting the skin, may be associated with various comorbidities (for instance, depression, psoriatic arthritis, Crohn's disease and, in severe psoriasis, metabolic syndrome and cardiovascular diseases), which often presents a therapeutic challenge to physicians.Written by renowned experts, this volume gives a comprehensive overview of psoriasis and its various comorbidities. It describes the treatment modalities for mild and moderate-to-severe psoriasis, including topical, phototherapeutic and conventional systemic treatments (e.g. acitretine, methotrexate and cyclosporine), as well as biological therapies (e.g. alefacept, efalizumab, etanercept, adalimumab and infliximab). The chapters on biological therapies focus on key safety issues. Further chapters focus on such topics as the management of childhood psoriasis and psoriasis in distinctive locations, such as the scalp, face, flexures, palm/soles and nails. Finally, future therapeutic modalities, with the focus on small molecules and potential biological therapies, are discussed.This publication will make significant reading to dermatologists and all physicians dealing with psoriasis, such as general practitioners, psychiatrists, rheumatologists, cardiologists and diabetologists.

In this issue of Dermatologic Clinics, guest editor Dr. Jeffrey M. Cohen brings his considerable expertise to the topic of Psoriasis: Contemporary and Future Therapies. Top experts in the field discuss oral therapies for psoriasis; phototherapy for psoriasis in the era of biologics; the psoriasis treatment pipeline; psoriasis comorbidities and their impact on treatment; underdiagnosis and undertreatment of traditional cardiovascular risk factors in psoriasis; and much more. Contains 14 relevant, practice-oriented topics including biologics for psoriasis; psoriasis genetics and the impact of genetics on comorbidities and treatment; psoriasis therapies in the pediatric population; disparities in psoriasis treatment; immune checkpoint inhibitor-induced psoriasis; and more. Provides in-depth clinical reviews on psoriasis: contemporary and future therapies, offering actionable insights for clinical practice. Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

Psoriasis can be managed in most patients so they can live productive lives. In Coping with Psoriasis, Dr. Cram covers how the disease starts, choosing the right doctor, treatment options, the importance of treating the emotional symptoms, the role of special diets, alternative therapies, and advances in treatment. Index, glossary, resource section.

This WHO Global report on psoriasis brings the public health impact of psoriasis into focus. The report is written to help raise awareness of the range of ways that psoriasis can affect peoples' lives. It intends to empower policy-makers with practical solutions to improve the health care and social inclusion of people living with psoriasis in their populations. The report highlights that much of the suffering caused by this common and complex disease can be avoided. Improving access to early diagnosis and appropriate treatment for psoriasis requires universally accessible health-care systems that provide people-centered care for patients with complex, lifelong conditions. Governments also have a key role to play in seeking to address the unnecessary social consequences of psoriasis by the challenging the myths and behaviors that lead to the exclusion of patients from healthcare settings and daily life.

This extensively revised second edition provides an up-to-date and highly informative textbook on psoriasis. The understanding of the mechanisms behind the disease and the available treatment options have continued to develop rapidly in recent times, with this vital resource covering the latest in these management options, including targeted T-cell therapy, the use of immunomodulators, systemic therapies, and ultraviolet and laser therapy. In addition, it provides a detailed overview of the pathophysiology, comorbidities, epidemiology and triggers of the disease. Advances in Psoriasis: A Multisystemic Guide extensively details the scientific basis and practice management of psoriasis. It is therefore a vital resource for practicing and trainee dermatologists looking to develop their clinical knowledge of how to manage and treat these patients.